Eagle Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2017 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Eagle Pharmaceuticals (EGRX) Reports In-Line Q4 EPS
February 26, 2018 6:54 AM ESTEagle Pharmaceuticals (NASDAQ: EGRX) reported Q4 EPS of $1.00, in-line with the analyst estimate of $1.00. Revenue for the quarter came in at $46.8 million versus the consensus estimate of $52.91 million.
For earnings history and earnings-related data on Eagle Pharmaceuticals (EGRX) click here.
... More